/ 2 items

#IMCR↓

IMCR/ 08/21/2026 · 8:08 AM

Immunocore’s Kimmtrak Anchors Growth as Pipeline Eyes Bigger Markets

Immunocore’s Kimmtrak hit ~$400M in 2025 sales with strong 2026 momentum. Solid cash, advancing Phase 3 trials, and Wall Street Buy ratings signal further upside.

FATE/ 10/31/2025 · 9:15 AM

Biotech Upgrades: FATE, IMCR, IMRX Get Bullish Analyst Calls

Analysts upgrade Fate Therapeutics to Buy and initiate bullish coverage on Immunocore and Immuneering, citing promising drug trials and strong revenue potential in lupus and cancer treatments.